Hyderabad biotech firm, Japanese entity ink pact

UR Advanced Therapeutics (URAT), the Hyderabad-based biotech firm behind the BioVaram brand, and Japanese company Teijin have signed an agreement to leverage each company’s strengths to offer solutions in both countries.

Specifically, the agreement aims to explore opportunities to expand the use of Teijin Group’s implantable medical devices and regenerative medicine products in India, as well as to introduce BioVaram’s product portfolio to the Japanese market.

Teijin and URAT will explore regulatory approval and commercialization of Teijin Medical Technologies cardiovascular repair patch Synfolium in India; and opportunities to expand the use of Japan Tissue Engineering Co.’s regenerative medicine products in India. They will work to develop and commercialize BioVaram technologies in Japan, including exosome-based diagnostics and therapies, Extracellular Matrix mimics, and bioderived materials such as Type I atelocollagen.

“By combining the expertise of both companies, we are confident in our ability to deliver innovative treatments that meet unmet medical needs in both countries,” said Takayuki Nakano, mission manager and general manager of Teijin Regenerative Medicine and Implantable Medical Device Division.

“The partnership enables Teijin to bring BioVaram products to global markets while strengthening our capabilities in research, innovation and scalable manufacturing of advanced tissue engineering products,” said URAT founder and CEO Jaganmohan Reddy.

The two companies will evaluate business feasibility, regulatory pathways, technical integration and market needs to advance these initiatives. The companies said in a statement on Thursday, November 13, 2025, that they will also collaborate on product development and manufacturing in cell and gene therapy and will pursue plans to introduce Synfolium in India.